# REXULTI Drug General Use-results Survey (Excessive Motor Activity or Physically/Verbally Aggressive Behavior Due to Rapid Changes in Mood, Irritability, and/or Outbursts Associated With Dementia Due to Alzheimer's Disease)

> **NCT06875986** · — · RECRUITING · sponsor: **Otsuka Pharmaceutical Co., Ltd.** · enrollment: 200 (estimated)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** Brexpiprazole (Rexulti)

## Key facts

- **NCT ID:** NCT06875986
- **Lead sponsor:** Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-17
- **Primary completion:** 2027-09-30
- **Final completion:** 2028-09-23
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06875986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06875986, "REXULTI Drug General Use-results Survey (Excessive Motor Activity or Physically/Verbally Aggressive Behavior Due to Rapid Changes in Mood, Irritability, and/or Outbursts Associated With Dementia Due to Alzheimer's Disease)". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT06875986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*